As of 3:59pm ET
| +0.05 / +0.68%|
The 3 analysts offering 12-month price forecasts for ADMA Biologics Inc have a median target of 14.00, with a high estimate of 15.00 and a low estimate of 12.50. The median estimate represents a +89.19% increase from the last price of 7.40.
The current consensus among 4 polled investment analysts is to Buy stock in ADMA Biologics Inc. This rating has held steady since September, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.